Work

Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.6_suppl.20

Authors: Mark T. Fleming, Howard I. Scher, Karim Fizazi, Mary-Ellen Taplin, David Forer, Mohammad Hirmand, Johann Sebastian De Bono

Institutions: Virginia Oncology Associates, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, Université Paris-Sud, Dana-Farber Cancer Institute, Medivation, Inc. (United States), Institute of Cancer Research

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2467444511

Cites:

Cited by: 7

Related to: 10